101ST GENERAL ASSEMBLY
State of Illinois
2019 and 2020
HB5005

 

Introduced 2/18/2020, by Rep. Lindsey LaPointe

 

SYNOPSIS AS INTRODUCED:
 
See Index

    Creates the Prescription Drug Repository Program Act. Requires the Department of Public Health to establish a prescription drug repository program, under which a healthcare facility may donate a prescription drug or supplies needed to administer a prescription drug for use by an individual who meets eligibility criteria specified by the Department. Sets forth requirements that prescription drugs or supplies must meet in order to be accepted and dispensed under the program. Provides that no drugs or supplies donated under the prescription drug repository program may be resold. Provides that nothing in the Act requires that a pharmacy or pharmacist participate in the prescription drug repository program. Provides for civil and criminal immunity for drug and supply manufacturers and pharmacists in relation to the donation, acceptance, or dispensing of prescription drugs or supplies under the prescription drug repository program. Amends the Pharmacy Practice Act, the Wholesale Drug Distribution Licensing Act, the Senior Pharmaceutical Assistance Act, the Illinois Food, Drug and Cosmetic Act, the Illinois Controlled Substances Act, and the Cannabis and Controlled Substances Tort Claims Act to provide that persons engaged in donating or accepting, or packaging, repackaging, or labeling, prescription drugs to the extent permitted or required under the Prescription Drug Repository Program Act are exempt from provisions of those other Acts that might prohibit or otherwise regulate such activity.


LRB101 17248 SPS 66652 b

FISCAL NOTE ACT MAY APPLY

 

 

A BILL FOR

 

HB5005LRB101 17248 SPS 66652 b

1    AN ACT concerning health.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 1. Short title. This Act may be cited as the
5Prescription Drug Repository Program Act.
 
6    Section 5. Definitions. In this Act:
7    "Department" means the Department of Public Health.
8    "Dispense" has the meaning given to that term in the
9Pharmacy Practice Act.
10    "Healthcare facility" means an assisted living facility,
11hospice, rehabilitation facility, or long-term care facility.
12    "Pharmacist" means an individual licensed to engage in the
13practice of pharmacy under the Pharmacy Practice Act.
14    "Pharmacy" means a pharmacy registered in this State under
15the Pharmacy Practice Act.
16    "Practitioner" means a person licensed in this State to
17prescribe and administer drugs or licensed in another state and
18recognized by this State as a person authorized to prescribe
19and administer drugs.
20    "Prescription drug" means any prescribed drug that may be
21legally dispensed by a pharmacy. "Prescription drug" does not
22include drugs for the treatment of cancer that can only be
23dispensed to a patient registered with the drug manufacturer in

 

 

HB5005- 2 -LRB101 17248 SPS 66652 b

1accordance with federal Food and Drug Administration
2requirements.
3    "Program" means the prescription drug repository program
4established under this Act.
 
5    Section 10. Prescription drug repository program. The
6Department shall establish and maintain a prescription drug
7repository program, under which a healthcare facility may
8donate a prescription drug or supplies needed to administer a
9prescription drug for use by an individual who meets
10appropriate eligibility criteria. Donations may be made on the
11premises of a pharmacy that elects to participate in the
12program and meets appropriate requirements. The pharmacy may
13charge an individual who receives a prescription drug or
14supplies needed to administer a prescription drug under this
15Act a handling fee that may not exceed an appropriate amount. A
16pharmacy that receives a donated prescription drug or supplies
17needed to administer a prescription drug under this Act may
18distribute the prescription drug or supplies to another
19eligible pharmacy for use under the program.
 
20    Section 15. Requirements for accepting and dispensing
21prescription drugs and supplies. A prescription drug or
22supplies needed to administer a prescription drug may be
23accepted and dispensed under the program only if all of the
24following requirements are met:

 

 

HB5005- 3 -LRB101 17248 SPS 66652 b

1        (1) The prescription drug or supplies needed to
2    administer a prescription drug are in their original,
3    unopened, sealed, and tamper-evident unit-dose packaging
4    or, if packaged in single-unit doses, the single-unit-dose
5    packaging is unopened.
6        (2) The prescription drug bears an expiration date that
7    is later than 6 months after the date that the drug was
8    donated.
9        (3) The prescription drug or supplies needed to
10    administer a prescription drug are not adulterated or
11    misbranded, as determined by a pharmacist employed by, or
12    under contract with, the pharmacy where the drug or
13    supplies are accepted or dispensed. The pharmacist must
14    inspect the drug or supplies before the drug or supplies
15    are dispensed.
16        (4) The prescription drug or supplies needed to
17    administer a prescription drug are prescribed by a
18    practitioner for use by an eligible individual.
 
19    Section 20. Resale of donated drugs or supplies prohibited.
20No prescription drug or supplies needed to administer a
21prescription drug that are donated for use under this Act may
22be resold.
 
23    Section 25. Participation in program not required. Nothing
24in this Act requires that a pharmacy or pharmacist participate

 

 

HB5005- 4 -LRB101 17248 SPS 66652 b

1in the prescription drug repository program.
 
2    Section 30. Immunity.
3    (a) Except in cases of willful and wanton misconduct, a
4manufacturer of a drug or supply is not subject to criminal or
5civil liability for injury, death, or loss to a person or
6property for matters related to the donation, acceptance, or
7dispensing of a prescription drug or supply manufactured by the
8manufacturer that is donated under this Act, including
9liability for failure to transfer or communicate product or
10consumer information or the expiration date of the donated
11prescription drug. The provisions of this subsection shall
12apply only to the donation, acceptance, or dispensing of drugs
13or supplies provided without fee or compensation, except for
14those fees made allowable under Section 10 of this Act.
15Immunity granted under this subsection is solely applicable to
16the donation, acceptance, or dispensing of a drug or supply
17under this Act and is not a general waiver of liability that
18would have existed under the original prescription.
19    (b) A pharmacist or other health care professional working
20in a pharmacy participating in the program dispensing,
21furnishing, or otherwise providing in good faith without fee or
22compensation donated prescription drugs to eligible
23individuals under this Act shall not be subject to professional
24or civil liability, except for willful or wanton misconduct.
 

 

 

HB5005- 5 -LRB101 17248 SPS 66652 b

1    Section 90. The Pharmacy Practice Act is amended by
2changing Section 4 as follows:
 
3    (225 ILCS 85/4)  (from Ch. 111, par. 4124)
4    (Section scheduled to be repealed on January 1, 2023)
5    Sec. 4. Exemptions. Nothing contained in any Section of
6this Act shall apply to, or in any manner interfere with:
7        (a) the lawful practice of any physician licensed to
8    practice medicine in all of its branches, dentist,
9    podiatric physician, veterinarian, or therapeutically or
10    diagnostically certified optometrist within the limits of
11    his or her license, or prevent him or her from supplying to
12    his or her bona fide patients such drugs, medicines, or
13    poisons as may seem to him appropriate;
14        (b) the sale of compressed gases;
15        (c) the sale of patent or proprietary medicines and
16    household remedies when sold in original and unbroken
17    packages only, if such patent or proprietary medicines and
18    household remedies be properly and adequately labeled as to
19    content and usage and generally considered and accepted as
20    harmless and nonpoisonous when used according to the
21    directions on the label, and also do not contain opium or
22    coca leaves, or any compound, salt or derivative thereof,
23    or any drug which, according to the latest editions of the
24    following authoritative pharmaceutical treatises and
25    standards, namely, The United States

 

 

HB5005- 6 -LRB101 17248 SPS 66652 b

1    Pharmacopoeia/National Formulary (USP/NF), the United
2    States Dispensatory, and the Accepted Dental Remedies of
3    the Council of Dental Therapeutics of the American Dental
4    Association or any or either of them, in use on the
5    effective date of this Act, or according to the existing
6    provisions of the Federal Food, Drug, and Cosmetic Act and
7    Regulations of the Department of Health and Human Services,
8    Food and Drug Administration, promulgated thereunder now
9    in effect, is designated, described or considered as a
10    narcotic, hypnotic, habit forming, dangerous, or poisonous
11    drug;
12        (d) the sale of poultry and livestock remedies in
13    original and unbroken packages only, labeled for poultry
14    and livestock medication;
15        (e) the sale of poisonous substances or mixture of
16    poisonous substances, in unbroken packages, for
17    nonmedicinal use in the arts or industries or for
18    insecticide purposes; provided, they are properly and
19    adequately labeled as to content and such nonmedicinal
20    usage, in conformity with the provisions of all applicable
21    federal, state and local laws and regulations promulgated
22    thereunder now in effect relating thereto and governing the
23    same, and those which are required under such applicable
24    laws and regulations to be labeled with the word "Poison",
25    are also labeled with the word "Poison" printed thereon in
26    prominent type and the name of a readily obtainable

 

 

HB5005- 7 -LRB101 17248 SPS 66652 b

1    antidote with directions for its administration;
2        (f) the delegation of limited prescriptive authority
3    by a physician licensed to practice medicine in all its
4    branches to a physician assistant under Section 7.5 of the
5    Physician Assistant Practice Act of 1987. This delegated
6    authority under Section 7.5 of the Physician Assistant
7    Practice Act of 1987 may, but is not required to, include
8    prescription of controlled substances, as defined in
9    Article II of the Illinois Controlled Substances Act, in
10    accordance with a written supervision agreement;
11        (g) the delegation of prescriptive authority by a
12    physician licensed to practice medicine in all its branches
13    or a licensed podiatric physician to an advanced practice
14    registered nurse in accordance with a written
15    collaborative agreement under Sections 65-35 and 65-40 of
16    the Nurse Practice Act; and
17        (h) the sale or distribution of dialysate or devices
18    necessary to perform home peritoneal renal dialysis for
19    patients with end-stage renal disease, provided that all of
20    the following conditions are met:
21            (1) the dialysate, comprised of dextrose or
22        icodextrin, or devices are approved or cleared by the
23        federal Food and Drug Administration, as required by
24        federal law;
25            (2) the dialysate or devices are lawfully held by a
26        manufacturer or the manufacturer's agent, which is

 

 

HB5005- 8 -LRB101 17248 SPS 66652 b

1        properly registered with the Board as a manufacturer,
2        third-party logistics provider, or wholesaler;
3            (3) the dialysate or devices are held and delivered
4        to the manufacturer or the manufacturer's agent in the
5        original, sealed packaging from the manufacturing
6        facility;
7            (4) the dialysate or devices are delivered only
8        upon receipt of a physician's prescription by a
9        licensed pharmacy in which the prescription is
10        processed in accordance with provisions set forth in
11        this Act, and the transmittal of an order from the
12        licensed pharmacy to the manufacturer or the
13        manufacturer's agent; and
14            (5) the manufacturer or the manufacturer's agent
15        delivers the dialysate or devices directly to: (i) a
16        patient with end-stage renal disease, or his or her
17        designee, for the patient's self-administration of the
18        dialysis therapy or (ii) a health care provider or
19        institution for administration or delivery of the
20        dialysis therapy to a patient with end-stage renal
21        disease; and .
22        (i) the donation or acceptance, or the packaging,
23    repackaging, or labeling, of prescription drugs to the
24    extent permitted or required under the Prescription Drug
25    Repository Program Act.
26        This paragraph (h) does not include any other drugs for

 

 

HB5005- 9 -LRB101 17248 SPS 66652 b

1    peritoneal dialysis, except dialysate, as described in
2    item (1) of this paragraph (h). All records of sales and
3    distribution of dialysate to patients made pursuant to this
4    paragraph (h) must be retained in accordance with Section
5    18 of this Act.
6(Source: P.A. 100-218, eff. 8-18-17; 100-513, eff. 1-1-18;
7100-863, eff. 8-14-18; 101-420, eff. 8-16-19.)
 
8    Section 91. The Wholesale Drug Distribution Licensing Act
9is amended by changing Section 15 as follows:
 
10    (225 ILCS 120/15)  (from Ch. 111, par. 8301-15)
11    (Section scheduled to be repealed on January 1, 2023)
12    Sec. 15. Definitions. As used in this Act:
13    "Authentication" means the affirmative verification,
14before any wholesale distribution of a prescription drug
15occurs, that each transaction listed on the pedigree has
16occurred.
17    "Authorized distributor of record" means a wholesale
18distributor with whom a manufacturer has established an ongoing
19relationship to distribute the manufacturer's prescription
20drug. An ongoing relationship is deemed to exist between a
21wholesale distributor and a manufacturer when the wholesale
22distributor, including any affiliated group of the wholesale
23distributor, as defined in Section 1504 of the Internal Revenue
24Code, complies with the following:

 

 

HB5005- 10 -LRB101 17248 SPS 66652 b

1        (1) The wholesale distributor has a written agreement
2    currently in effect with the manufacturer evidencing the
3    ongoing relationship; and
4        (2) The wholesale distributor is listed on the
5    manufacturer's current list of authorized distributors of
6    record, which is updated by the manufacturer on no less
7    than a monthly basis.
8    "Blood" means whole blood collected from a single donor and
9processed either for transfusion or further manufacturing.
10    "Blood component" means that part of blood separated by
11physical or mechanical means.
12    "Board" means the State Board of Pharmacy of the Department
13of Professional Regulation.
14    "Chain pharmacy warehouse" means a physical location for
15prescription drugs that acts as a central warehouse and
16performs intracompany sales or transfers of the drugs to a
17group of chain or mail order pharmacies that have the same
18common ownership and control. Notwithstanding any other
19provision of this Act, a chain pharmacy warehouse shall be
20considered part of the normal distribution channel.
21    "Co-licensed partner or product" means an instance where
22one or more parties have the right to engage in the
23manufacturing or marketing of a prescription drug, consistent
24with the FDA's implementation of the Prescription Drug
25Marketing Act.
26    "Department" means the Department of Financial and

 

 

HB5005- 11 -LRB101 17248 SPS 66652 b

1Professional Regulation.
2    "Drop shipment" means the sale of a prescription drug to a
3wholesale distributor by the manufacturer of the prescription
4drug or that manufacturer's co-licensed product partner, that
5manufacturer's third party logistics provider, or that
6manufacturer's exclusive distributor or by an authorized
7distributor of record that purchased the product directly from
8the manufacturer or one of these entities whereby the wholesale
9distributor or chain pharmacy warehouse takes title but not
10physical possession of such prescription drug and the wholesale
11distributor invoices the pharmacy, chain pharmacy warehouse,
12or other person authorized by law to dispense or administer
13such drug to a patient and the pharmacy, chain pharmacy
14warehouse, or other authorized person receives delivery of the
15prescription drug directly from the manufacturer, that
16manufacturer's third party logistics provider, or that
17manufacturer's exclusive distributor or from an authorized
18distributor of record that purchased the product directly from
19the manufacturer or one of these entities.
20    "Drug sample" means a unit of a prescription drug that is
21not intended to be sold and is intended to promote the sale of
22the drug.
23    "Facility" means a facility of a wholesale distributor
24where prescription drugs are stored, handled, repackaged, or
25offered for sale, or a facility of a third-party logistics
26provider where prescription drugs are stored or handled.

 

 

HB5005- 12 -LRB101 17248 SPS 66652 b

1    "FDA" means the United States Food and Drug Administration.
2    "Manufacturer" means a person licensed or approved by the
3FDA to engage in the manufacture of drugs or devices,
4consistent with the definition of "manufacturer" set forth in
5the FDA's regulations and guidances implementing the
6Prescription Drug Marketing Act. "Manufacturer" does not
7include anyone who is engaged in the packaging, repackaging, or
8labeling of prescription drugs only to the extent required
9under the Prescription Drug Repository Program Act.
10    "Manufacturer's exclusive distributor" means anyone who
11contracts with a manufacturer to provide or coordinate
12warehousing, distribution, or other services on behalf of a
13manufacturer and who takes title to that manufacturer's
14prescription drug, but who does not have general responsibility
15to direct the sale or disposition of the manufacturer's
16prescription drug. A manufacturer's exclusive distributor must
17be licensed as a wholesale distributor under this Act and, in
18order to be considered part of the normal distribution channel,
19must also be an authorized distributor of record.
20    "Normal distribution channel" means a chain of custody for
21a prescription drug that goes, directly or by drop shipment,
22from (i) a manufacturer of the prescription drug, (ii) that
23manufacturer to that manufacturer's co-licensed partner, (iii)
24that manufacturer to that manufacturer's third party logistics
25provider, or (iv) that manufacturer to that manufacturer's
26exclusive distributor to:

 

 

HB5005- 13 -LRB101 17248 SPS 66652 b

1        (1) a pharmacy or to other designated persons
2    authorized by law to dispense or administer the drug to a
3    patient;
4        (2) a wholesale distributor to a pharmacy or other
5    designated persons authorized by law to dispense or
6    administer the drug to a patient;
7        (3) a wholesale distributor to a chain pharmacy
8    warehouse to that chain pharmacy warehouse's intracompany
9    pharmacy to a patient or other designated persons
10    authorized by law to dispense or administer the drug to a
11    patient;
12        (4) a chain pharmacy warehouse to the chain pharmacy
13    warehouse's intracompany pharmacy or other designated
14    persons authorized by law to dispense or administer the
15    drug to the patient;
16        (5) an authorized distributor of record to one other
17    authorized distributor of record to an office-based health
18    care practitioner authorized by law to dispense or
19    administer the drug to the patient; or
20        (6) an authorized distributor to a pharmacy or other
21    persons licensed to dispense or administer the drug.
22    "Pedigree" means a document or electronic file containing
23information that records each wholesale distribution of any
24given prescription drug from the point of origin to the final
25wholesale distribution point of any given prescription drug.
26    "Person" means and includes a natural person, partnership,

 

 

HB5005- 14 -LRB101 17248 SPS 66652 b

1association, corporation, or any other legal business entity.
2    "Pharmacy distributor" means any pharmacy licensed in this
3State or hospital pharmacy that is engaged in the delivery or
4distribution of prescription drugs either to any other pharmacy
5licensed in this State or to any other person or entity
6including, but not limited to, a wholesale drug distributor
7engaged in the delivery or distribution of prescription drugs
8who is involved in the actual, constructive, or attempted
9transfer of a drug in this State to other than the ultimate
10consumer except as otherwise provided for by law.
11    "Prescription drug" means any human drug, including any
12biological product (except for blood and blood components
13intended for transfusion or biological products that are also
14medical devices), required by federal law or regulation to be
15dispensed only by a prescription, including finished dosage
16forms and bulk drug substances subject to Section 503 of the
17Federal Food, Drug and Cosmetic Act.
18    "Repackage" means repackaging or otherwise changing the
19container, wrapper, or labeling to further the distribution of
20a prescription drug, excluding that completed by the pharmacist
21responsible for dispensing the product to a patient.
22    "Secretary" means the Secretary of Financial and
23Professional Regulation.
24    "Third-party logistics provider" means anyone who
25contracts with a prescription drug manufacturer to provide or
26coordinate warehousing, distribution, or other services on

 

 

HB5005- 15 -LRB101 17248 SPS 66652 b

1behalf of a manufacturer, but does not take title to the
2prescription drug or have general responsibility to direct the
3prescription drug's sale or disposition.
4    "Wholesale distribution" means the distribution of
5prescription drugs to persons other than a consumer or patient,
6but does not include any of the following:
7        (1) Intracompany sales of prescription drugs, meaning
8    (i) any transaction or transfer between any division,
9    subsidiary, parent, or affiliated or related company under
10    the common ownership and control of a corporate entity or
11    (ii) any transaction or transfer between co-licensees of a
12    co-licensed product.
13        (2) The sale, purchase, distribution, trade, or
14    transfer of a prescription drug or offer to sell, purchase,
15    distribute, trade, or transfer a prescription drug for
16    emergency medical reasons.
17        (3) The distribution of prescription drug samples by
18    manufacturers' representatives.
19        (4) Drug returns, when conducted by a hospital, health
20    care entity, or charitable institution in accordance with
21    federal regulation.
22        (5) The sale of minimal quantities of prescription
23    drugs by licensed pharmacies to licensed practitioners for
24    office use or other licensed pharmacies.
25        (6) The sale, purchase, or trade of a drug, an offer to
26    sell, purchase, or trade a drug, or the dispensing of a

 

 

HB5005- 16 -LRB101 17248 SPS 66652 b

1    drug pursuant to a prescription.
2        (7) The sale, transfer, merger, or consolidation of all
3    or part of the business of a pharmacy or pharmacies from or
4    with another pharmacy or pharmacies, whether accomplished
5    as a purchase and sale of stock or business assets.
6        (8) The sale, purchase, distribution, trade, or
7    transfer of a prescription drug from one authorized
8    distributor of record to one additional authorized
9    distributor of record when the manufacturer has stated in
10    writing to the receiving authorized distributor of record
11    that the manufacturer is unable to supply the prescription
12    drug and the supplying authorized distributor of record
13    states in writing that the prescription drug being supplied
14    had until that time been exclusively in the normal
15    distribution channel.
16        (9) The delivery of or the offer to deliver a
17    prescription drug by a common carrier solely in the common
18    carrier's usual course of business of transporting
19    prescription drugs when the common carrier does not store,
20    warehouse, or take legal ownership of the prescription
21    drug.
22        (10) The sale or transfer from a retail pharmacy, mail
23    order pharmacy, or chain pharmacy warehouse of expired,
24    damaged, returned, or recalled prescription drugs to the
25    original manufacturer, the originating wholesale
26    distributor, or a third party returns processor.

 

 

HB5005- 17 -LRB101 17248 SPS 66652 b

1        (11) The donation of prescription drugs to the extent
2    permitted under the Prescription Drug Repository Program
3    Act.
4    "Wholesale drug distributor" means anyone engaged in the
5wholesale distribution of prescription drugs into, out of, or
6within the State, including without limitation manufacturers;
7repackers; own label distributors; jobbers; private label
8distributors; brokers; warehouses, including manufacturers'
9and distributors' warehouses; manufacturer's exclusive
10distributors; and authorized distributors of record; drug
11wholesalers or distributors; independent wholesale drug
12traders; specialty wholesale distributors; and retail
13pharmacies that conduct wholesale distribution; and chain
14pharmacy warehouses that conduct wholesale distribution. In
15order to be considered part of the normal distribution channel,
16a wholesale distributor must also be an authorized distributor
17of record.
18(Source: P.A. 101-420, eff. 8-16-19.)
 
19    Section 92. The Senior Pharmaceutical Assistance Act is
20amended by changing Section 10 as follows:
 
21    (320 ILCS 50/10)
22    Sec. 10. Definitions. In this Act:
23    "Manufacturer" includes:
24        (1) An entity that is engaged in (a) the production,

 

 

HB5005- 18 -LRB101 17248 SPS 66652 b

1    preparation, propagation, compounding, conversion, or
2    processing of prescription drug products (i) directly or
3    indirectly by extraction from substances of natural
4    origin, (ii) independently by means of chemical synthesis,
5    or (iii) by combination of extraction and chemical
6    synthesis; or (b) the packaging, repackaging, labeling or
7    re-labeling, or distribution of prescription drug
8    products.
9        (2) The entity holding legal title to or possession of
10    the national drug code number for the covered prescription
11    drug.
12    The term does not include a wholesale distributor of drugs,
13drugstore chain organization, or retail pharmacy licensed by
14the State. The term also does not include anyone who is engaged
15in the packaging, repackaging, or labeling of prescription
16drugs only to the extent required under the Prescription Drug
17Repository Program Act.
18    "Prescription drug" means a drug that may be dispensed only
19upon prescription by an authorized prescriber and that is
20approved for safety and effectiveness as a prescription drug
21under Section 505 or 507 of the Federal Food, Drug and Cosmetic
22Act.
23    "Senior citizen" or "senior" means a person 65 years of age
24or older.
25(Source: P.A. 92-594, eff. 6-27-02.)
 

 

 

HB5005- 19 -LRB101 17248 SPS 66652 b

1    Section 93. The Illinois Food, Drug and Cosmetic Act is
2amended by changing Section 16 as follows:
 
3    (410 ILCS 620/16)  (from Ch. 56 1/2, par. 516)
4    Sec. 16. (a) The Director is hereby authorized to
5promulgate regulations exempting from any labeling or
6packaging requirement of this Act drugs and devices which are
7(i) , in accordance with the practice of the trade, to be
8processed, labeled or repacked in substantial quantities at
9establishments other than those where originally processed or
10packaged on condition that such drugs and devices are not
11adulterated or misbranded under the provisions of this Act upon
12removal from such processing, labeling or repacking
13establishment or (ii) packaged, repackaged, or labeled to the
14extent required under the Prescription Drug Repository Program
15Act.
16    (b) Drugs and device labeling or packaging exemptions
17adopted under the Federal Act and supplements thereto or
18revisions thereof shall apply to drugs and devices in Illinois
19except insofar as modified or rejected by regulations
20promulgated by the Director.
21    (c) A drug intended for use by man which (A) is a
22habit-forming drug to which Section 15 (d) applies; or (B)
23because of its toxicity or other potentiality for harmful
24effect or the method of its use or the collateral measures
25necessary to its use is not safe for use except under the

 

 

HB5005- 20 -LRB101 17248 SPS 66652 b

1supervision of a practitioner licensed by law to administer
2such drug; or (C) is limited by an approved application under
3Section 505 of the Federal Act or Section 17 of this Act to use
4under the professional supervision of a practitioner licensed
5by law to administer such drug, shall be dispensed only in
6accordance with the provisions of the "Illinois Controlled
7Substances Act". The act of dispensing a drug contrary to the
8provisions of this paragraph shall be deemed to be an act which
9results in a drug being misbranded while held for sale.
10    (d) Any drug dispensed by filling or refilling a written or
11oral prescription of a practitioner licensed by law to
12administer such drug shall be exempt from the requirements of
13Section 15, except subsections (a), (k) and (l) and clauses (2)
14and (3) of subsection (i), and the packaging requirements of
15subsections (g), (h) and (q), if the drug bears a label
16containing the proprietary name or names, or if there is none,
17the established name or names of the drugs, the dosage and
18quantity, unless the prescribing practitioner, in the interest
19of the health of the patient, directs otherwise in writing, the
20name and address of the dispenser, the serial number and date
21of the prescription or of its filling, the name of the
22prescriber and, if stated in the prescription, the name of the
23patient, and the directions for use and the cautionary
24statements, if any, contained in such prescription. This
25exemption shall not apply to any drug dispensed in the course
26of the conduct of business of dispensing drugs pursuant to

 

 

HB5005- 21 -LRB101 17248 SPS 66652 b

1diagnosis by mail, or to a drug dispensed in violation of
2subsection (a) of this Section.
3    (e) The Director may by regulation remove drugs subject to
4Section 15 (d) and Section 17 from the requirements of
5subsection (c) of this Section when such requirements are not
6necessary for the protection of the public health.
7    (f) A drug which is subject to subsection (c) of this
8Section shall be deemed to be misbranded if at any time before
9dispensing its label fails to bear the statement "Caution:
10Federal Law Prohibits Dispensing Without Prescription" or
11"Caution: State Law Prohibits Dispensing Without
12Prescription". A drug to which subsection (c) of this Section
13does not apply shall be deemed to be misbranded if at any time
14prior to dispensing its label bears the caution statement
15quoted in the preceding sentence.
16    (g) Nothing in this Section shall be construed to relieve
17any person from any requirement prescribed by or under
18authority of law with respect to controlled substances now
19included or which may hereafter be included within the
20classifications of controlled substances cannabis as defined
21in applicable Federal laws relating to controlled substances or
22cannabis or the Cannabis Control Act.
23(Source: P.A. 84-1308.)
 
24    Section 94. The Illinois Controlled Substances Act is
25amended by changing Section 102 as follows:
 

 

 

HB5005- 22 -LRB101 17248 SPS 66652 b

1    (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
2    Sec. 102. Definitions. As used in this Act, unless the
3context otherwise requires:
4    (a) "Addict" means any person who habitually uses any drug,
5chemical, substance or dangerous drug other than alcohol so as
6to endanger the public morals, health, safety or welfare or who
7is so far addicted to the use of a dangerous drug or controlled
8substance other than alcohol as to have lost the power of self
9control with reference to his or her addiction.
10    (b) "Administer" means the direct application of a
11controlled substance, whether by injection, inhalation,
12ingestion, or any other means, to the body of a patient,
13research subject, or animal (as defined by the Humane
14Euthanasia in Animal Shelters Act) by:
15        (1) a practitioner (or, in his or her presence, by his
16    or her authorized agent),
17        (2) the patient or research subject pursuant to an
18    order, or
19        (3) a euthanasia technician as defined by the Humane
20    Euthanasia in Animal Shelters Act.
21    (c) "Agent" means an authorized person who acts on behalf
22of or at the direction of a manufacturer, distributor,
23dispenser, prescriber, or practitioner. It does not include a
24common or contract carrier, public warehouseman or employee of
25the carrier or warehouseman.

 

 

HB5005- 23 -LRB101 17248 SPS 66652 b

1    (c-1) "Anabolic Steroids" means any drug or hormonal
2substance, chemically and pharmacologically related to
3testosterone (other than estrogens, progestins,
4corticosteroids, and dehydroepiandrosterone), and includes:
5    (i) 3[beta],17-dihydroxy-5a-androstane, 
6    (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, 
7    (iii) 5[alpha]-androstan-3,17-dione, 
8    (iv) 1-androstenediol (3[beta], 
9        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
10    (v) 1-androstenediol (3[alpha], 
11        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
12    (vi) 4-androstenediol  
13        (3[beta],17[beta]-dihydroxy-androst-4-ene), 
14    (vii) 5-androstenediol  
15        (3[beta],17[beta]-dihydroxy-androst-5-ene), 
16    (viii) 1-androstenedione  
17        ([5alpha]-androst-1-en-3,17-dione), 
18    (ix) 4-androstenedione  
19        (androst-4-en-3,17-dione), 
20    (x) 5-androstenedione  
21        (androst-5-en-3,17-dione), 
22    (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- 
23        hydroxyandrost-4-en-3-one), 
24    (xii) boldenone (17[beta]-hydroxyandrost- 
25        1,4,-diene-3-one), 
26    (xiii) boldione (androsta-1,4- 

 

 

HB5005- 24 -LRB101 17248 SPS 66652 b

1        diene-3,17-dione), 
2    (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 
3        [beta]-hydroxyandrost-4-en-3-one), 
4    (xv) clostebol (4-chloro-17[beta]- 
5        hydroxyandrost-4-en-3-one), 
6    (xvi) dehydrochloromethyltestosterone (4-chloro- 
7        17[beta]-hydroxy-17[alpha]-methyl- 
8        androst-1,4-dien-3-one), 
9    (xvii) desoxymethyltestosterone 
10    (17[alpha]-methyl-5[alpha] 
11        -androst-2-en-17[beta]-ol)(a.k.a., madol), 
12    (xviii) [delta]1-dihydrotestosterone (a.k.a.  
13        '1-testosterone') (17[beta]-hydroxy- 
14        5[alpha]-androst-1-en-3-one), 
15    (xix) 4-dihydrotestosterone (17[beta]-hydroxy- 
16        androstan-3-one), 
17    (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- 
18        5[alpha]-androstan-3-one), 
19    (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- 
20        hydroxyestr-4-ene), 
21    (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- 
22        1[beta],17[beta]-dihydroxyandrost-4-en-3-one), 
23    (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], 
24        17[beta]-dihydroxyandrost-1,4-dien-3-one), 
25    (xxiv) furazabol (17[alpha]-methyl-17[beta]- 
26        hydroxyandrostano[2,3-c]-furazan), 

 

 

HB5005- 25 -LRB101 17248 SPS 66652 b

1    (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one, 
2    (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- 
3        androst-4-en-3-one), 
4    (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- 
5        dihydroxy-estr-4-en-3-one), 
6    (xxviii) mestanolone (17[alpha]-methyl-17[beta]- 
7        hydroxy-5-androstan-3-one), 
8    (xxix) mesterolone (1amethyl-17[beta]-hydroxy- 
9        [5a]-androstan-3-one), 
10    (xxx) methandienone (17[alpha]-methyl-17[beta]- 
11        hydroxyandrost-1,4-dien-3-one), 
12    (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- 
13        dihydroxyandrost-5-ene), 
14    (xxxii) methenolone (1-methyl-17[beta]-hydroxy- 
15        5[alpha]-androst-1-en-3-one), 
16    (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- 
17        dihydroxy-5a-androstane, 
18    (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy 
19        -5a-androstane, 
20    (xxxv) 17[alpha]-methyl-3[beta],17[beta]- 
21        dihydroxyandrost-4-ene), 
22    (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- 
23        methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), 
24    (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- 
25        hydroxyestra-4,9(10)-dien-3-one), 
26    (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- 

 

 

HB5005- 26 -LRB101 17248 SPS 66652 b

1        hydroxyestra-4,9-11-trien-3-one), 
2    (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- 
3        hydroxyandrost-4-en-3-one), 
4    (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- 
5        hydroxyestr-4-en-3-one), 
6    (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  
7        (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- 
8        androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- 
9        1-testosterone'), 
10    (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), 
11    (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- 
12        dihydroxyestr-4-ene), 
13    (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- 
14        dihydroxyestr-4-ene), 
15    (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- 
16        dihydroxyestr-5-ene), 
17    (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- 
18        dihydroxyestr-5-ene), 
19    (xlvii) 19-nor-4,9(10)-androstadienedione  
20        (estra-4,9(10)-diene-3,17-dione), 
21    (xlviii) 19-nor-4-androstenedione (estr-4- 
22        en-3,17-dione), 
23    (xlix) 19-nor-5-androstenedione (estr-5- 
24        en-3,17-dione), 
25    (l) norbolethone (13[beta], 17a-diethyl-17[beta]- 
26        hydroxygon-4-en-3-one), 

 

 

HB5005- 27 -LRB101 17248 SPS 66652 b

1    (li) norclostebol (4-chloro-17[beta]- 
2        hydroxyestr-4-en-3-one), 
3    (lii) norethandrolone (17[alpha]-ethyl-17[beta]- 
4        hydroxyestr-4-en-3-one), 
5    (liii) normethandrolone (17[alpha]-methyl-17[beta]- 
6        hydroxyestr-4-en-3-one), 
7    (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- 
8        2-oxa-5[alpha]-androstan-3-one), 
9    (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- 
10        dihydroxyandrost-4-en-3-one), 
11    (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- 
12        17[beta]-hydroxy-(5[alpha]-androstan-3-one), 
13    (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- 
14        (5[alpha]-androst-2-eno[3,2-c]-pyrazole), 
15    (lviii) stenbolone (17[beta]-hydroxy-2-methyl- 
16        (5[alpha]-androst-1-en-3-one), 
17    (lix) testolactone (13-hydroxy-3-oxo-13,17- 
18        secoandrosta-1,4-dien-17-oic 
19        acid lactone), 
20    (lx) testosterone (17[beta]-hydroxyandrost- 
21        4-en-3-one), 
22    (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- 
23        diethyl-17[beta]-hydroxygon- 
24        4,9,11-trien-3-one), 
25    (lxii) trenbolone (17[beta]-hydroxyestr-4,9, 
26        11-trien-3-one). 

 

 

HB5005- 28 -LRB101 17248 SPS 66652 b

1    Any person who is otherwise lawfully in possession of an
2anabolic steroid, or who otherwise lawfully manufactures,
3distributes, dispenses, delivers, or possesses with intent to
4deliver an anabolic steroid, which anabolic steroid is
5expressly intended for and lawfully allowed to be administered
6through implants to livestock or other nonhuman species, and
7which is approved by the Secretary of Health and Human Services
8for such administration, and which the person intends to
9administer or have administered through such implants, shall
10not be considered to be in unauthorized possession or to
11unlawfully manufacture, distribute, dispense, deliver, or
12possess with intent to deliver such anabolic steroid for
13purposes of this Act.
14    (d) "Administration" means the Drug Enforcement
15Administration, United States Department of Justice, or its
16successor agency.
17    (d-5) "Clinical Director, Prescription Monitoring Program"
18means a Department of Human Services administrative employee
19licensed to either prescribe or dispense controlled substances
20who shall run the clinical aspects of the Department of Human
21Services Prescription Monitoring Program and its Prescription
22Information Library.
23    (d-10) "Compounding" means the preparation and mixing of
24components, excluding flavorings, (1) as the result of a
25prescriber's prescription drug order or initiative based on the
26prescriber-patient-pharmacist relationship in the course of

 

 

HB5005- 29 -LRB101 17248 SPS 66652 b

1professional practice or (2) for the purpose of, or incident
2to, research, teaching, or chemical analysis and not for sale
3or dispensing. "Compounding" includes the preparation of drugs
4or devices in anticipation of receiving prescription drug
5orders based on routine, regularly observed dispensing
6patterns. Commercially available products may be compounded
7for dispensing to individual patients only if both of the
8following conditions are met: (i) the commercial product is not
9reasonably available from normal distribution channels in a
10timely manner to meet the patient's needs and (ii) the
11prescribing practitioner has requested that the drug be
12compounded.
13    (e) "Control" means to add a drug or other substance, or
14immediate precursor, to a Schedule whether by transfer from
15another Schedule or otherwise.
16    (f) "Controlled Substance" means (i) a drug, substance,
17immediate precursor, or synthetic drug in the Schedules of
18Article II of this Act or (ii) a drug or other substance, or
19immediate precursor, designated as a controlled substance by
20the Department through administrative rule. The term does not
21include distilled spirits, wine, malt beverages, or tobacco, as
22those terms are defined or used in the Liquor Control Act of
231934 and the Tobacco Products Tax Act of 1995.
24    (f-5) "Controlled substance analog" means a substance:
25        (1) the chemical structure of which is substantially
26    similar to the chemical structure of a controlled substance

 

 

HB5005- 30 -LRB101 17248 SPS 66652 b

1    in Schedule I or II;
2        (2) which has a stimulant, depressant, or
3    hallucinogenic effect on the central nervous system that is
4    substantially similar to or greater than the stimulant,
5    depressant, or hallucinogenic effect on the central
6    nervous system of a controlled substance in Schedule I or
7    II; or
8        (3) with respect to a particular person, which such
9    person represents or intends to have a stimulant,
10    depressant, or hallucinogenic effect on the central
11    nervous system that is substantially similar to or greater
12    than the stimulant, depressant, or hallucinogenic effect
13    on the central nervous system of a controlled substance in
14    Schedule I or II.
15    (g) "Counterfeit substance" means a controlled substance,
16which, or the container or labeling of which, without
17authorization bears the trademark, trade name, or other
18identifying mark, imprint, number or device, or any likeness
19thereof, of a manufacturer, distributor, or dispenser other
20than the person who in fact manufactured, distributed, or
21dispensed the substance.
22    (h) "Deliver" or "delivery" means the actual, constructive
23or attempted transfer of possession of a controlled substance,
24with or without consideration, whether or not there is an
25agency relationship. The term does not include the donation of
26prescription drugs to the extent permitted under the

 

 

HB5005- 31 -LRB101 17248 SPS 66652 b

1Prescription Drug Repository Program Act.
2    (i) "Department" means the Illinois Department of Human
3Services (as successor to the Department of Alcoholism and
4Substance Abuse) or its successor agency.
5    (j) (Blank).
6    (k) "Department of Corrections" means the Department of
7Corrections of the State of Illinois or its successor agency.
8    (l) "Department of Financial and Professional Regulation"
9means the Department of Financial and Professional Regulation
10of the State of Illinois or its successor agency.
11    (m) "Depressant" means any drug that (i) causes an overall
12depression of central nervous system functions, (ii) causes
13impaired consciousness and awareness, and (iii) can be
14habit-forming or lead to a substance abuse problem, including
15but not limited to alcohol, cannabis and its active principles
16and their analogs, benzodiazepines and their analogs,
17barbiturates and their analogs, opioids (natural and
18synthetic) and their analogs, and chloral hydrate and similar
19sedative hypnotics.
20    (n) (Blank).
21    (o) "Director" means the Director of the Illinois State
22Police or his or her designated agents.
23    (p) "Dispense" means to deliver a controlled substance to
24an ultimate user or research subject by or pursuant to the
25lawful order of a prescriber, including the prescribing,
26administering, packaging, labeling, or compounding necessary

 

 

HB5005- 32 -LRB101 17248 SPS 66652 b

1to prepare the substance for that delivery.
2    (q) "Dispenser" means a practitioner who dispenses.
3    (r) "Distribute" means to deliver, other than by
4administering or dispensing, a controlled substance.
5    (s) "Distributor" means a person who distributes.
6    (t) "Drug" means (1) substances recognized as drugs in the
7official United States Pharmacopoeia, Official Homeopathic
8Pharmacopoeia of the United States, or official National
9Formulary, or any supplement to any of them; (2) substances
10intended for use in diagnosis, cure, mitigation, treatment, or
11prevention of disease in man or animals; (3) substances (other
12than food) intended to affect the structure of any function of
13the body of man or animals and (4) substances intended for use
14as a component of any article specified in clause (1), (2), or
15(3) of this subsection. It does not include devices or their
16components, parts, or accessories.
17    (t-3) "Electronic health record" or "EHR" means an
18electronic record of health-related information on an
19individual that is created, gathered, managed, and consulted by
20authorized health care clinicians and staff.
21    (t-4) "Emergency medical services personnel" has the
22meaning ascribed to it in the Emergency Medical Services (EMS)
23Systems Act.
24    (t-5) "Euthanasia agency" means an entity certified by the
25Department of Financial and Professional Regulation for the
26purpose of animal euthanasia that holds an animal control

 

 

HB5005- 33 -LRB101 17248 SPS 66652 b

1facility license or animal shelter license under the Animal
2Welfare Act. A euthanasia agency is authorized to purchase,
3store, possess, and utilize Schedule II nonnarcotic and
4Schedule III nonnarcotic drugs for the sole purpose of animal
5euthanasia.
6    (t-10) "Euthanasia drugs" means Schedule II or Schedule III
7substances (nonnarcotic controlled substances) that are used
8by a euthanasia agency for the purpose of animal euthanasia.
9    (u) "Good faith" means the prescribing or dispensing of a
10controlled substance by a practitioner in the regular course of
11professional treatment to or for any person who is under his or
12her treatment for a pathology or condition other than that
13individual's physical or psychological dependence upon or
14addiction to a controlled substance, except as provided herein:
15and application of the term to a pharmacist shall mean the
16dispensing of a controlled substance pursuant to the
17prescriber's order which in the professional judgment of the
18pharmacist is lawful. The pharmacist shall be guided by
19accepted professional standards including, but not limited to
20the following, in making the judgment:
21        (1) lack of consistency of prescriber-patient
22    relationship,
23        (2) frequency of prescriptions for same drug by one
24    prescriber for large numbers of patients,
25        (3) quantities beyond those normally prescribed,
26        (4) unusual dosages (recognizing that there may be

 

 

HB5005- 34 -LRB101 17248 SPS 66652 b

1    clinical circumstances where more or less than the usual
2    dose may be used legitimately),
3        (5) unusual geographic distances between patient,
4    pharmacist and prescriber,
5        (6) consistent prescribing of habit-forming drugs.
6    (u-0.5) "Hallucinogen" means a drug that causes markedly
7altered sensory perception leading to hallucinations of any
8type.
9    (u-1) "Home infusion services" means services provided by a
10pharmacy in compounding solutions for direct administration to
11a patient in a private residence, long-term care facility, or
12hospice setting by means of parenteral, intravenous,
13intramuscular, subcutaneous, or intraspinal infusion.
14    (u-5) "Illinois State Police" means the State Police of the
15State of Illinois, or its successor agency.
16    (v) "Immediate precursor" means a substance:
17        (1) which the Department has found to be and by rule
18    designated as being a principal compound used, or produced
19    primarily for use, in the manufacture of a controlled
20    substance;
21        (2) which is an immediate chemical intermediary used or
22    likely to be used in the manufacture of such controlled
23    substance; and
24        (3) the control of which is necessary to prevent,
25    curtail or limit the manufacture of such controlled
26    substance.

 

 

HB5005- 35 -LRB101 17248 SPS 66652 b

1    (w) "Instructional activities" means the acts of teaching,
2educating or instructing by practitioners using controlled
3substances within educational facilities approved by the State
4Board of Education or its successor agency.
5    (x) "Local authorities" means a duly organized State,
6County or Municipal peace unit or police force.
7    (y) "Look-alike substance" means a substance, other than a
8controlled substance which (1) by overall dosage unit
9appearance, including shape, color, size, markings or lack
10thereof, taste, consistency, or any other identifying physical
11characteristic of the substance, would lead a reasonable person
12to believe that the substance is a controlled substance, or (2)
13is expressly or impliedly represented to be a controlled
14substance or is distributed under circumstances which would
15lead a reasonable person to believe that the substance is a
16controlled substance. For the purpose of determining whether
17the representations made or the circumstances of the
18distribution would lead a reasonable person to believe the
19substance to be a controlled substance under this clause (2) of
20subsection (y), the court or other authority may consider the
21following factors in addition to any other factor that may be
22relevant:
23        (a) statements made by the owner or person in control
24    of the substance concerning its nature, use or effect;
25        (b) statements made to the buyer or recipient that the
26    substance may be resold for profit;

 

 

HB5005- 36 -LRB101 17248 SPS 66652 b

1        (c) whether the substance is packaged in a manner
2    normally used for the illegal distribution of controlled
3    substances;
4        (d) whether the distribution or attempted distribution
5    included an exchange of or demand for money or other
6    property as consideration, and whether the amount of the
7    consideration was substantially greater than the
8    reasonable retail market value of the substance.
9    Clause (1) of this subsection (y) shall not apply to a
10noncontrolled substance in its finished dosage form that was
11initially introduced into commerce prior to the initial
12introduction into commerce of a controlled substance in its
13finished dosage form which it may substantially resemble.
14    Nothing in this subsection (y) prohibits the dispensing or
15distributing of noncontrolled substances by persons authorized
16to dispense and distribute controlled substances under this
17Act, provided that such action would be deemed to be carried
18out in good faith under subsection (u) if the substances
19involved were controlled substances.
20    Nothing in this subsection (y) or in this Act prohibits the
21manufacture, preparation, propagation, compounding,
22processing, packaging, advertising or distribution of a drug or
23drugs by any person registered pursuant to Section 510 of the
24Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
25    (y-1) "Mail-order pharmacy" means a pharmacy that is
26located in a state of the United States that delivers,

 

 

HB5005- 37 -LRB101 17248 SPS 66652 b

1dispenses or distributes, through the United States Postal
2Service or other common carrier, to Illinois residents, any
3substance which requires a prescription.
4    (z) "Manufacture" means the production, preparation,
5propagation, compounding, conversion or processing of a
6controlled substance other than methamphetamine, either
7directly or indirectly, by extraction from substances of
8natural origin, or independently by means of chemical
9synthesis, or by a combination of extraction and chemical
10synthesis, and includes any packaging or repackaging of the
11substance or labeling of its container, except that this term
12does not include:
13        (1) by an ultimate user, the preparation or compounding
14    of a controlled substance for his or her own use; or
15        (2) by a practitioner, or his or her authorized agent
16    under his or her supervision, the preparation,
17    compounding, packaging, or labeling of a controlled
18    substance:
19            (a) as an incident to his or her administering or
20        dispensing of a controlled substance in the course of
21        his or her professional practice; or
22            (b) as an incident to lawful research, teaching or
23        chemical analysis and not for sale; or .
24        (3) the packaging, repackaging, or labeling of
25    prescription drugs only to the extent required under the
26    Prescription Drug Repository Program Act.

 

 

HB5005- 38 -LRB101 17248 SPS 66652 b

1    (z-1) (Blank).
2    (z-5) "Medication shopping" means the conduct prohibited
3under subsection (a) of Section 314.5 of this Act.
4    (z-10) "Mid-level practitioner" means (i) a physician
5assistant who has been delegated authority to prescribe through
6a written delegation of authority by a physician licensed to
7practice medicine in all of its branches, in accordance with
8Section 7.5 of the Physician Assistant Practice Act of 1987,
9(ii) an advanced practice registered nurse who has been
10delegated authority to prescribe through a written delegation
11of authority by a physician licensed to practice medicine in
12all of its branches or by a podiatric physician, in accordance
13with Section 65-40 of the Nurse Practice Act, (iii) an advanced
14practice registered nurse certified as a nurse practitioner,
15nurse midwife, or clinical nurse specialist who has been
16granted authority to prescribe by a hospital affiliate in
17accordance with Section 65-45 of the Nurse Practice Act, (iv)
18an animal euthanasia agency, or (v) a prescribing psychologist.
19    (aa) "Narcotic drug" means any of the following, whether
20produced directly or indirectly by extraction from substances
21of vegetable origin, or independently by means of chemical
22synthesis, or by a combination of extraction and chemical
23synthesis:
24        (1) opium, opiates, derivatives of opium and opiates,
25    including their isomers, esters, ethers, salts, and salts
26    of isomers, esters, and ethers, whenever the existence of

 

 

HB5005- 39 -LRB101 17248 SPS 66652 b

1    such isomers, esters, ethers, and salts is possible within
2    the specific chemical designation; however the term
3    "narcotic drug" does not include the isoquinoline
4    alkaloids of opium;
5        (2) (blank);
6        (3) opium poppy and poppy straw;
7        (4) coca leaves, except coca leaves and extracts of
8    coca leaves from which substantially all of the cocaine and
9    ecgonine, and their isomers, derivatives and salts, have
10    been removed;
11        (5) cocaine, its salts, optical and geometric isomers,
12    and salts of isomers;
13        (6) ecgonine, its derivatives, their salts, isomers,
14    and salts of isomers;
15        (7) any compound, mixture, or preparation which
16    contains any quantity of any of the substances referred to
17    in subparagraphs (1) through (6).
18    (bb) "Nurse" means a registered nurse licensed under the
19Nurse Practice Act.
20    (cc) (Blank).
21    (dd) "Opiate" means any substance having an addiction
22forming or addiction sustaining liability similar to morphine
23or being capable of conversion into a drug having addiction
24forming or addiction sustaining liability.
25    (ee) "Opium poppy" means the plant of the species Papaver
26somniferum L., except its seeds.

 

 

HB5005- 40 -LRB101 17248 SPS 66652 b

1    (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
2solution or other liquid form of medication intended for
3administration by mouth, but the term does not include a form
4of medication intended for buccal, sublingual, or transmucosal
5administration.
6    (ff) "Parole and Pardon Board" means the Parole and Pardon
7Board of the State of Illinois or its successor agency.
8    (gg) "Person" means any individual, corporation,
9mail-order pharmacy, government or governmental subdivision or
10agency, business trust, estate, trust, partnership or
11association, or any other entity.
12    (hh) "Pharmacist" means any person who holds a license or
13certificate of registration as a registered pharmacist, a local
14registered pharmacist or a registered assistant pharmacist
15under the Pharmacy Practice Act.
16    (ii) "Pharmacy" means any store, ship or other place in
17which pharmacy is authorized to be practiced under the Pharmacy
18Practice Act.
19    (ii-5) "Pharmacy shopping" means the conduct prohibited
20under subsection (b) of Section 314.5 of this Act.
21    (ii-10) "Physician" (except when the context otherwise
22requires) means a person licensed to practice medicine in all
23of its branches.
24    (jj) "Poppy straw" means all parts, except the seeds, of
25the opium poppy, after mowing.
26    (kk) "Practitioner" means a physician licensed to practice

 

 

HB5005- 41 -LRB101 17248 SPS 66652 b

1medicine in all its branches, dentist, optometrist, podiatric
2physician, veterinarian, scientific investigator, pharmacist,
3physician assistant, advanced practice registered nurse,
4licensed practical nurse, registered nurse, emergency medical
5services personnel, hospital, laboratory, or pharmacy, or
6other person licensed, registered, or otherwise lawfully
7permitted by the United States or this State to distribute,
8dispense, conduct research with respect to, administer or use
9in teaching or chemical analysis, a controlled substance in the
10course of professional practice or research.
11    (ll) "Pre-printed prescription" means a written
12prescription upon which the designated drug has been indicated
13prior to the time of issuance; the term does not mean a written
14prescription that is individually generated by machine or
15computer in the prescriber's office.
16    (mm) "Prescriber" means a physician licensed to practice
17medicine in all its branches, dentist, optometrist,
18prescribing psychologist licensed under Section 4.2 of the
19Clinical Psychologist Licensing Act with prescriptive
20authority delegated under Section 4.3 of the Clinical
21Psychologist Licensing Act, podiatric physician, or
22veterinarian who issues a prescription, a physician assistant
23who issues a prescription for a controlled substance in
24accordance with Section 303.05, a written delegation, and a
25written collaborative agreement required under Section 7.5 of
26the Physician Assistant Practice Act of 1987, an advanced

 

 

HB5005- 42 -LRB101 17248 SPS 66652 b

1practice registered nurse with prescriptive authority
2delegated under Section 65-40 of the Nurse Practice Act and in
3accordance with Section 303.05, a written delegation, and a
4written collaborative agreement under Section 65-35 of the
5Nurse Practice Act, an advanced practice registered nurse
6certified as a nurse practitioner, nurse midwife, or clinical
7nurse specialist who has been granted authority to prescribe by
8a hospital affiliate in accordance with Section 65-45 of the
9Nurse Practice Act and in accordance with Section 303.05, or an
10advanced practice registered nurse certified as a nurse
11practitioner, nurse midwife, or clinical nurse specialist who
12has full practice authority pursuant to Section 65-43 of the
13Nurse Practice Act.
14    (nn) "Prescription" means a written, facsimile, or oral
15order, or an electronic order that complies with applicable
16federal requirements, of a physician licensed to practice
17medicine in all its branches, dentist, podiatric physician or
18veterinarian for any controlled substance, of an optometrist in
19accordance with Section 15.1 of the Illinois Optometric
20Practice Act of 1987, of a prescribing psychologist licensed
21under Section 4.2 of the Clinical Psychologist Licensing Act
22with prescriptive authority delegated under Section 4.3 of the
23Clinical Psychologist Licensing Act, of a physician assistant
24for a controlled substance in accordance with Section 303.05, a
25written delegation, and a written collaborative agreement
26required under Section 7.5 of the Physician Assistant Practice

 

 

HB5005- 43 -LRB101 17248 SPS 66652 b

1Act of 1987, of an advanced practice registered nurse with
2prescriptive authority delegated under Section 65-40 of the
3Nurse Practice Act who issues a prescription for a controlled
4substance in accordance with Section 303.05, a written
5delegation, and a written collaborative agreement under
6Section 65-35 of the Nurse Practice Act, of an advanced
7practice registered nurse certified as a nurse practitioner,
8nurse midwife, or clinical nurse specialist who has been
9granted authority to prescribe by a hospital affiliate in
10accordance with Section 65-45 of the Nurse Practice Act and in
11accordance with Section 303.05 when required by law, or of an
12advanced practice registered nurse certified as a nurse
13practitioner, nurse midwife, or clinical nurse specialist who
14has full practice authority pursuant to Section 65-43 of the
15Nurse Practice Act.
16    (nn-5) "Prescription Information Library" (PIL) means an
17electronic library that contains reported controlled substance
18data.
19    (nn-10) "Prescription Monitoring Program" (PMP) means the
20entity that collects, tracks, and stores reported data on
21controlled substances and select drugs pursuant to Section 316.
22    (oo) "Production" or "produce" means manufacture,
23planting, cultivating, growing, or harvesting of a controlled
24substance other than methamphetamine.
25    (pp) "Registrant" means every person who is required to
26register under Section 302 of this Act.

 

 

HB5005- 44 -LRB101 17248 SPS 66652 b

1    (qq) "Registry number" means the number assigned to each
2person authorized to handle controlled substances under the
3laws of the United States and of this State.
4    (qq-5) "Secretary" means, as the context requires, either
5the Secretary of the Department or the Secretary of the
6Department of Financial and Professional Regulation, and the
7Secretary's designated agents.
8    (rr) "State" includes the State of Illinois and any state,
9district, commonwealth, territory, insular possession thereof,
10and any area subject to the legal authority of the United
11States of America.
12    (rr-5) "Stimulant" means any drug that (i) causes an
13overall excitation of central nervous system functions, (ii)
14causes impaired consciousness and awareness, and (iii) can be
15habit-forming or lead to a substance abuse problem, including
16but not limited to amphetamines and their analogs,
17methylphenidate and its analogs, cocaine, and phencyclidine
18and its analogs.
19    (rr-10) "Synthetic drug" includes, but is not limited to,
20any synthetic cannabinoids or piperazines or any synthetic
21cathinones as provided for in Schedule I.
22    (ss) "Ultimate user" means a person who lawfully possesses
23a controlled substance for his or her own use or for the use of
24a member of his or her household or for administering to an
25animal owned by him or her or by a member of his or her
26household.

 

 

HB5005- 45 -LRB101 17248 SPS 66652 b

1(Source: P.A. 99-78, eff. 7-20-15; 99-173, eff. 7-29-15;
299-371, eff. 1-1-16; 99-480, eff. 9-9-15; 99-642, eff. 7-28-16;
3100-280, eff. 1-1-18; 100-453, eff. 8-25-17; 100-513, eff.
41-1-18; 100-789, eff. 1-1-19; 100-863, eff. 8-14-18.)
 
5    Section 95. The Cannabis and Controlled Substances Tort
6Claims Act is amended by changing Section 3 as follows:
 
7    (740 ILCS 20/3)  (from Ch. 70, par. 903)
8    Sec. 3. Definitions. As used in this Act, unless the
9context otherwise requires:
10    "Cannabis" includes marihuana, hashish, and other
11substances that are identified as including any parts of the
12plant Cannabis Sativa, whether growing or not, the seeds of
13that plant, the resin extracted from any part of that plant,
14and any compound, manufacture, salt, derivative, mixture, or
15preparation of that plant, its seeds, or resin, including
16tetrahydrocannabinol (THC) and all other cannabinol
17derivatives, including its naturally occurring or
18synthetically produced ingredients, whether produced directly
19or indirectly by extraction, independently by means of chemical
20synthesis, or by a combination of extraction and chemical
21synthesis. "Cannabis" does not include the mature stalks of
22that plant, fiber produced from those stalks, oil or cake made
23from the seeds of that plant, any other compound, manufacture,
24salt, derivative, mixture, or preparation of mature stalks

 

 

HB5005- 46 -LRB101 17248 SPS 66652 b

1(except the extracted resin), fiber, oil or cake, or the
2sterilized seeds of that plant that are incapable of
3germination.
4    "Controlled substance" means a drug, substance, or
5immediate precursor in the Schedules of Article II of the
6Illinois Controlled Substances Act.
7    "Counterfeit substance" means a controlled substance or
8the container or labeling of a controlled substance that,
9without authorization, bears the trademark, trade name, or
10other identifying mark, imprint, number, device, or any
11likeness thereof of a manufacturer, distributor, or dispenser
12other than the person who in fact manufactured, distributed, or
13dispensed the substance.
14    "Deliver" or "delivery" means the actual, constructive, or
15attempted transfer of possession of a controlled substance or
16cannabis, with or without consideration, whether or not there
17is an agency relationship. The term does not include the
18donation of prescription drugs to the extent permitted under
19the Prescription Drug Repository Program Act.
20    "Manufacture" means the production, preparation,
21propagation, compounding, conversion, or processing of a
22controlled substance, either directly or indirectly, by
23extraction from substances of natural origin, independently by
24means of chemical synthesis, or by a combination of extraction
25and chemical synthesis, and includes any packaging or
26repackaging of the substance or labeling of its container,

 

 

HB5005- 47 -LRB101 17248 SPS 66652 b

1except that the term does not include:
2        (1) by an ultimate user, the preparation or compounding
3    of a controlled substance for his own use;
4        (2) by a practitioner or his authorized agent under his
5    supervision, the preparation, compounding, packaging, or
6    labeling of a controlled substance:
7            (A) as an incident to his administering or
8        dispensing of a controlled substance in the course of
9        his professional practice; or
10            (B) as an incident to lawful research, teaching or
11        chemical analysis and not for sale; or
12        (3) the preparation, compounding, packaging, or
13    labeling of cannabis as an incident to lawful research,
14    teaching, or chemical analysis and not for sale; or .
15        (4) the packaging, repackaging, or labeling of
16    prescription drugs only to the extent required under the
17    Prescription Drug Repository Program Act.
18    "Owner" means a person who has possession of or any
19interest whatsoever in the property involved.
20    "Person" means an individual, a corporation, a government,
21a governmental subdivision or agency, a business trust, an
22estate, a trust, a partnership or association, or any other
23entity.
24    "Production" means planting, cultivating, tending, or
25harvesting.
26    "Property" means real property, including things growing

 

 

HB5005- 48 -LRB101 17248 SPS 66652 b

1on, affixed to, and found in land, and tangible or intangible
2personal property, including rights, services, privileges,
3interests, claims, and securities.
4(Source: P.A. 96-328, eff. 8-11-09.)

 

 

HB5005- 49 -LRB101 17248 SPS 66652 b

1 INDEX
2 Statutes amended in order of appearance
3    New Act
4    225 ILCS 85/4from Ch. 111, par. 4124
5    225 ILCS 120/15from Ch. 111, par. 8301-15
6    320 ILCS 50/10
7    410 ILCS 620/16from Ch. 56 1/2, par. 516
8    720 ILCS 570/102from Ch. 56 1/2, par. 1102
9    740 ILCS 20/3from Ch. 70, par. 903